Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk to expand China R&D

Novo Nordisk is to double the size of its R&D centre in China by 2015

Novo Nordisk is to double the size of its R&D centre in Beijing, China by 2015.

The diabetes specialist said the level of employees at the centre will increase from 100 to 200, with a focus on creating a new Diabetes Research Unit in the country.

 

A picture of a building housing a Diabetes Research Unit in China

Novo Nordisk R&D centre in China

 

"By doubling the current staff at our R&D centre, Novo Nordisk acknowledges the achievements of the Chinese staff since the centre was established in 1997," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Denmark-based Novo Nordisk.

"And once again, we demonstrate our long term commitment to take part in the scientific and technological development of China, while at the same time helping Novo Nordisk to get access to the tremendous resource of talents, ideas and innovation in China."

Since its establishment, the R&D centre has focused on building expertise in protein engineering and purification, as well as creating and improving monoclonal antibodies.

The expansion will see Novo Nordisk research biopharmaceutical approaches to develop new treatments against diabetes.

The company said the R&D team in China "will eventually take part in all aspects of drug discovery, from innovation to developing drug candidates for clinical studies in humans."

14th September 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...